TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06172348
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
Study: NCT06036784
Drug: MBX 1416 (Part A)
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
Study: NCT06036784
Drug: MBX 1416 (Part B)
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
Study: NCT06036784
Drug: MBX 1416 (Part C)
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
Study: NCT04305106
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
Study: NCT06184139
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol for induction of labor in late term pregnancies
Study: NCT04891497
Drug: Dimethyl Fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Study: NCT05228834
Drug: Voxelotor Only Product in Oral Dose Form
Normalized name: Voxelotor only product in oral dose form
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Study: NCT04512365
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
Study: NCT05055934
Drug: SHR-1314 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1314 injection
Study: NCT05090904
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05525234
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
Study: NCT00375323
Drug: NovoSeven
Normalized name: NovoSeven
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04405180
Drug: 20mg sodium nitrite tid
Normalized name: Sodium Nitrite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
Study: NCT05480865
Drug: BBP-398
Normalized name: BBP-812
DrugBank: BBP-812 (DB16983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBP-398 administered orally
Study: NCT05480865
Drug: sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sotorasib administered orally
Study: NCT06498323
Drug: tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thrombolytic agents administration
Study: NCT05526222
Drug: Jaktinib Hydrochloride Tablet
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered, twice a day
Study: NCT06222437
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: effectiveness of semaglutide in PCOS
Study: NCT05197504
Drug: atezolizumab plus bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
Study: NCT04660110
Drug: IPT with Dihydroartemisinin Piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
Study: NCT05467670
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
Study: NCT05467670
Drug: ALX148
Normalized name: Sirpa variant alx148
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
Study: NCT05114499
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 5mg qd
Study: NCT05988710
Drug: Buccal Buprenorphine 300 mcg
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine for 300mcg buccal administration
Study: NCT05988710
Drug: Buccal Buprenorphine 600 mcg
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine for 600mcg buccal administration
Study: NCT05988710
Drug: Buccal Buprenorphine 900 mcg
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
Study: NCT05988710
Drug: Oral immediate-release oxycodone 10mg
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate-release oxycodone for 10 mg oral administration
Study: NCT05988710
Drug: Buccal Buprenorphine 450mcg
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
Study: NCT05245734
Drug: Human Anti-D (rh) immunoglobulin
Normalized name: Human anti-D (rh) immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
Study: NCT06027307
Drug: Enavogliflozin
Normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
Study: NCT06671938
Drug: exidavnemab
Normalized name: Exidavnemab
DrugBank: Exidavnemab (DB19452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
Study: NCT05792995
Drug: Sindillimab
Normalized name: Sintilimab
DrugBank: Dill (DB10673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment regimen that includes immunotherapy.
Study: NCT06040034
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine given as bolus or continuous infusion.
Study: NCT04436965
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study: NCT04643418
Drug: MPB-1734
Normalized name: MPB-1523
DrugBank: MPB-1523 (DB18334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in a 21-day cycle
Study: NCT05742568
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
Study: NCT05742568
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
Study: NCT05742568
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Study: NCT05742568
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Study: NCT05742568
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Study: NCT05914675
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7\~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
Study: NCT05547061
Drug: Lu-177-DGUL
Normalized name: Lu 177
DrugBank: Lutetium Lu-177 (DB13982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
Study: NCT05547061
Drug: Ga-68-NGUL
Normalized name: Ga 68 DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
Study: NCT04684589
Drug: Tadalafil 20 MG
Normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
Study: NCT06730256
Drug: CAR-T cells Infusion chimeric antigen receptor T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cells Infusion chimeric antigen receptor T cells
Study: NCT05207904
Drug: Tislelizumab, paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
Study: NCT05786768
Drug: single infusion of Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single infusion of Rituximab 375 mg/m2
Study: NCT05786768
Drug: single infusion of Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single infusion of Obinutuzumab 300mg/1.73 m2
Study: NCT05567029
Drug: Risankizumab Dose A
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prefilled Syringe
Study: NCT05567029
Drug: Risankizumab Dose B
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prefilled Syringe
Study: NCT05861102
Drug: Jaktinib
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
Study: NCT05901584
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
Study: NCT05490134
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
Study: NCT05490134
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
Study: NCT05921149
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05921149
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05940896
Drug: Disitamab vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
Study: NCT04982172
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
Study: NCT04982172
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
Study: NCT06404840
Drug: nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimotuzumab (400 mg, iv, d1, qw)
Study: NCT06404840
Drug: AG chemotherapy
Normalized name: casein, Lactococcus lactis cultured, aged
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
Study: NCT04902729
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Study: NCT04902729
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
Study: NCT04618211
Drug: Deucrictibant
Normalized name: Deucrictibant
DrugBank: Deucrictibant (DB18303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: deucrictibant soft capsules for oral use
Study: NCT06330220
Drug: Aflibercept Injection [Eylea]
Normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection
Study: NCT06625814
Drug: Enlicitide Decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT04617925
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
Study: NCT06034977
Drug: ADI-PEG20
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lenvatinib + ADI-PEG20 combination treatment.
Study: NCT05580328
Drug: Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy
Normalized name: hematoporphyrin
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
Study: NCT06368882
Drug: Peg-Interferon α
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
Study: NCT05406505
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
Study: NCT05550441
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The experimental group received dapagliflozin (10 mg qd) for 1 year.
Study: NCT05149378
Drug: Venetoclax combined with azacitidine regimen
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
Study: NCT06333405
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI
Study: NCT06178783
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib oral solutions will be expectorated following the tasting.
Study: NCT05756569
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05123755
Drug: AV-001 Injection
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
Study: NCT06073470
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients with ADHD will receive 12-week treatment with methylphenidate.
Study: NCT04624906
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg oral capsules twice daily for 1 year
Study: NCT04624906
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m2 on days 1 and 2 of each cycle.
Study: NCT04624906
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
Study: NCT05606796
Drug: Latanoprost 0.005% Ophthalmic Solution
Normalized name: Latanoprost 0.005% Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
Study: NCT00001047
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001047
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001047
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05636150
Drug: Fruquintinib in Combination with S-1
Normalized name: fruquintinib 1 MG
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
Study: NCT03897491
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid powder for oral solution